Alvotech and Kamada announce agreement to commercialise six biosimilar products in Israel. The first product is expected to be launched in Israel in 2022.
Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, with STADA responsible for commercialisation.
Biocon and Evotec announce strategic licensing agreement for an early-stage biosimilar. Under this agreement, Biocon will take the asset through end-to-end development, IND filing, manufacturing and commercialisation and post-regulatory approval.
Biocon announces purchase of 60,000 square foot R&D site from Pfizer. The site in Chennai, India will house 250 scientists and is expected to be operational in a few months.
Pfizer and Polpharma announce licensing deal for natalizumab biosimilar. Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.
Celltrion announces patnership with Lonza for the production of Remsima®. Lonza will now work within Celltrion’s network to complement Celltrion’s own production capacity.
Alvotech and Prestige announce manufacturing partnership, under which Alvotech will be responsible for commercial manufacturing of Prestige’s biosimilars.
Mylan and Pfizer announce deal under which Mylan and UpJohn (a division of Pfizer) will merge to form NewCo (name to be announced). Under the deal, Pfizer shareholders will own 57% of the combined company, and Mylan shareholders 43%. Mylan CEO Heather Bresch will retire as part of the deal, and the new CEO will be Michael Goettler, current Upjohn group President. Mylan notes its biosimilars as bringing key growth to NewCo, including trastuzumab (Ogivri), bevacizumab (the India-approved and launched Abevmy), pegfilgrastim (Fulphila), and insulin glargine (Semglee, approved and launched in EU and elsewhere), and the pipeline biosimilars abatacept and aflibercept. Read more.
AbbVie announces agreement for the acquisition of Allergan for $63 billion in a cash and stock exchange.
Alvotech and Abdi Ibrahim announce partnership for biosimilar development and commercialisation in Turkey. Alvotech will be responsible for development and joint supply alongside Abdi Ibrahim, while Abdi Ibrahim will be responsible for registration and commercialisation of the products.
Xbrane and STADA announce expansion of biosimilar development partnership. This expansion will now include the development of Xbrane’s biosimilar candidates certolizumab pegol and nivolumab, as well as other biosimilars.
Sagent Pharmaceuticals announces acquisition of manufacturing site in North Carolina providing Sagent with the potential to produce both small molecule and biologic products. This is the first FDA approved facility in the Nichi-Iko Group.
Selexis SA announces it has executed two commercial licence agreements with Turgut Pharmaceuticals for the development of biosimilar antibodies. This expansion of the partnership between the two companies aims to develop a biosimilar for the treatment of metastatic HER2-positive cancer and a checkpoint inhibitor for certain cancers.
Samsung Bioepis partners with C-Bridge to commercialise biosimilars in China. Under the deal, C-Bridge will develop a new company, AffaMed Therapeutics to launch candidates such as ranibizumab, eculizumab and trastuzumab biosimilars.
Alvotech announces development in biosimilar pipeline with $300 million raised through a private bond offering.
Samsung Bioepis announces partnership with 3SBio to commercialise biosimilars in China. Under the agreement, Samsung Bioepis will be be responsible for manufacturing and supplying the products, while 3SBio will be responsible for regulatory registration and commercialisation.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.